Eli Lilly and Novo Nordisk say overweight or diabetic patients taking GLP-1 weight-loss drugs showed lower biological age than placebo groups on molecular "aging clocks." Novo's Nikolaj Roed puts the gap at roughly two to three years. The data is company-reported, and results varied widely by clock and organ.
Do Weight-Loss Drugs Really Slow Biological Aging?
According to the drugmakers, GLP-1 drugs slow biological aging, at least as measured by molecular tests. That is a claim about company-reported readouts, not proof that the medicines reverse aging.
MIT Technology Review reported on October 6, 2026 that Eli Lilly and Novo Nordisk both say patients on their GLP-1 drugs age less quickly, based on readouts from "aging clocks." In both companies' analyses, people who were overweight or had diabetes and took a GLP-1 had a lower biological age than people given a placebo.
The finding matters because these medicines are already among the most widely used drugs in the world. If their effects reach beyond weight and blood sugar, the question of what they are for changes. But several caveats come with that, and the details below set out what the companies have and have not shown.
Biological age is an estimate of how worn a person's body is at the molecular level. It can differ from chronological age, which is simply the number of years since birth.
How Do Aging Clocks Measure Biological Age?
Aging clocks estimate biological age from molecular signals in the body, using either chemical changes to DNA or levels of key proteins. Each approach yields a number that can be compared between treatment groups.
Read next Laika's Wildwood: Stop-Motion Fantasy at TIFF 2026The first and best-known type reads changes to DNA that build up as time passes. The newer type tracks the levels of key proteins. MIT Technology Review described the protein-based tests as more recent versions of the technology.
The distinction matters because the two kinds of clock do not necessarily agree. A DNA-based clock and a protein-based clock look at different biology, so they can return different answers for the same patient group. The source reports that the size of the gap between drug and placebo varied widely depending on which clock was used.
| Clock type | What it measures | Notes from the report |
|---|---|---|
| DNA-based | Changes to DNA that accumulate with time | The original approach |
| Protein-based | Levels of key proteins | Described as newer versions |
How Big Is the Anti-Aging Effect of GLP-1 Drugs?
Across the companies' analyses, the average difference was around two to three years of biological age, according to Nikolaj Roed, a global project leader at Novo Nordisk. That is an average across a wide spread of results.
As of October 2026, the figures come from the drugmakers themselves. Roed said the company has been seeing "improved biological age in our patients across trials and across different tissues." That points to consistency across several studies and body tissues, though the underlying data was not detailed in the MIT Technology Review summary.
Independent expertise lends the number some weight. Steve Horvath, a professor at the University of California, Los Angeles, said: "Two years is a pretty strong effect, in my book." Horvath's name is closely tied to the field of aging clocks, which makes his reading of the size of the effect worth noting.
Still, a few years' difference on a clock is not the same as a few extra years of life. The clocks are estimates, and the report stresses that readouts differed by clock type and by organ tested. Some measures presumably showed more benefit than others, and some showed less. A single headline number smooths over that variation.
Could GLP-1 Drugs Act on the Basic Causes of Aging?
Possibly, and many scientists speculate so, but the clock data alone cannot settle it. The new readouts add to wide speculation that GLP-1 drugs act on basic causes of aging and might be a true longevity treatment.
The reasoning runs like this. If a single class of drugs improves markers across different tissues, as Novo says it has seen, the effect may be more than a side effect of weight loss. It could reflect something fundamental about how the body ages. That is a hypothesis, and the summary reported by MIT Technology Review does not establish the mechanism.
There is also a plain alternative. Obesity and diabetes are themselves linked with poorer health, so patients who lose weight and gain better metabolic control might simply look biologically younger on a clock as a result. Distinguishing between "the drug slows aging" and "the drug treats conditions that speed aging" is the central scientific question. The company data, as reported, does not separate the two.
What Are the Limits of These Early Findings?
The main limits are the source of the data, the wide variation between clocks and organs, and the fact that a clock reading is a proxy rather than a health outcome. These findings are early.
First, the numbers come from Eli Lilly and Novo Nordisk, which sell these drugs. Company-reported readouts are not the same as peer-reviewed, independently replicated studies, and readers should treat them accordingly.
Second, the spread is large. The difference between treated and placebo patients varied widely by clock and by organ, so "two to three years" is a summary, not a guarantee for any one person.
Third, the participants were overweight or diabetic. The source does not say whether healthy, normal-weight people would see any effect, so no conclusion about the general population is supported.
Fourth, a younger reading on a clock does not by itself show that patients live longer or stay healthier. That would take long-term outcome data, which the summary does not describe.
What This Means for Weight-Loss Drug Makers and Patients
This section is analysis, not reported fact.
For drugmakers, the aging-clock results offer a new storyline for products that are already commercially significant. Lilly and Novo have an incentive to promote any benefit beyond weight loss, which is one more reason independent verification matters.
For patients, the practical message is modest. People who take GLP-1 drugs for obesity or diabetes may gain an additional, as-yet-unproven benefit, but nobody should start or keep a prescription for anti-aging reasons on the strength of company readouts. Decisions about these drugs belong with a doctor, based on established medical indications.
For researchers, the next steps are clear: independent studies, publication of the full data, comparison across clock types, and, eventually, trials that track real outcomes such as disease and lifespan. Until then, the careful reading is that GLP-1 drugs slow biological aging on some measures, according to their makers, and that the question of what this means for human longevity remains open.
Source: MIT Technology Review
